Literature DB >> 17309900

Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry.

Mihai Gheorghiade1, William T Abraham, Nancy M Albert, Wendy Gattis Stough, Barry H Greenberg, Christopher M O'Connor, Lilin She, Clyde W Yancy, James Young, Gregg C Fonarow.   

Abstract

AIMS: Hyponatraemia has been shown to be an independent predictor of mortality in selected patients with heart failure enrolled in clinical trials. The predictive value of hyponatraemia has not been evaluated in unselected patients hospitalized with heart failure. METHODS AND
RESULTS: OPTIMIZE-HF is a registry and performance-improvement programme for patients hospitalized with heart failure and includes a subgroup with 60-90 day follow-up data. The relationship between admission serum sodium concentration and clinical outcomes was analysed in 48,612 patients from 259 hospitals. Admission serum sodium levels were analysed both as a continuous variable and by grouping patients with admission Na < 135 and Na > or = 135 mmol/L. Patients with hyponatraemia (Na <135 mmol/L) at the time of hospital admission had modest differences in baseline clinical characteristics and management during hospitalization compared with patients who had serum sodium > or =135 mmol/L. Patients with hyponatraemia were more likely to be Caucasian, have lower admission systolic blood pressure, and receive intravenous inotropes during hospitalization. Patients with hyponatraemia had significantly higher rates of in-hospital and follow-up mortality and longer hospital stays, although no difference in re-admission rates was observed. After adjusting for differences with multivariable analysis, the risk of in-hospital death increased by 19.5%, the risk of follow-up mortality by 10%, and the risk of death or rehospitalization by 8% for each 3 mmol/L decrease in admission serum sodium below 140 mmol/L.
CONCLUSION: Hyponatraemia in hospitalized patients with heart failure is relatively common and is associated with longer hospital stays and higher in-hospital and early post-discharge mortality. Re-admission rates were equally high in patients with or without hyponatraemia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17309900     DOI: 10.1093/eurheartj/ehl542

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  121 in total

1.  Renal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failure.

Authors:  Lisa C Costello-Boerrigter; Guido Boerrigter; Alessandro Cataliotti; Gail J Harty; John C Burnett
Journal:  Circ Heart Fail       Date:  2010-02-22       Impact factor: 8.790

2.  Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study.

Authors:  William T Abraham; Juan M Aranda; John P Boehmer; Uri Elkayam; Edward M Gilbert; Stephen S Gottlieb; Gerd Hasenfuss; Marrick Kukin; Brian D Lowes; John B O'Connell; Luigi Tavazzi; Arthur M Feldman; Barry Ticho; Cesare Orlandi
Journal:  Clin Transl Sci       Date:  2010-10       Impact factor: 4.689

Review 3.  Targeting hyponatremia and hemodynamics in acute decompensated heart failure: is there a role for vasopressin antagonists?

Authors:  Gregory Valania; Manmeet Singh; Mara T Slawsky
Journal:  Curr Heart Fail Rep       Date:  2011-09

Review 4.  Improvement of hyponatremia is associated with lower mortality risk in patients with acute decompensated heart failure: a meta-analysis of cohort studies.

Authors:  Jinhui Wang; Weijian Zhou; Xiaoning Yin
Journal:  Heart Fail Rev       Date:  2019-03       Impact factor: 4.214

5.  An Appraisal of Biomarker-Based Risk-Scoring Models in Chronic Heart Failure: Which One Is Best?

Authors:  Barbara S Doumouras; Douglas S Lee; Wayne C Levy; Ana C Alba
Journal:  Curr Heart Fail Rep       Date:  2018-02

6.  Outcomes of correcting hyponatremia in patients with myocardial infarction.

Authors:  Waqas Qureshi; Syed Hassan; Fatima Khalid; Mohamed Faher Almahmoud; Bhavik Shah; Ra'ad Tashman; Nikhil Ambulgekar; Mostafa El-Refai; Chetan Mittal; Zaid Alirhayim
Journal:  Clin Res Cardiol       Date:  2013-05-08       Impact factor: 5.460

Review 7.  Pharmacologic Approaches to Electrolyte Abnormalities in Heart Failure.

Authors:  Justin L Grodin
Journal:  Curr Heart Fail Rep       Date:  2016-08

Review 8.  Vasopressin receptor antagonists in patients with chronic heart failure.

Authors:  R De Vecchis; C Cantatrione; D Mazzei
Journal:  Herz       Date:  2016-09-15       Impact factor: 1.443

9.  Hyponatremia in the outpatient setting: clinical characteristics, risk factors, and outcome.

Authors:  Vildan Tasdemir; Ali Kemal Oguz; Irmak Sayın; Ihsan Ergun
Journal:  Int Urol Nephrol       Date:  2015-10-22       Impact factor: 2.370

10.  Plasma bioactive adrenomedullin as a prognostic biomarker in acute heart failure.

Authors:  Wesley H Self; Alan B Storrow; Oliver Hartmann; Tyler W Barrett; Gregory J Fermann; Alan S Maisel; Joachim Struck; Andreas Bergmann; Sean P Collins
Journal:  Am J Emerg Med       Date:  2015-10-24       Impact factor: 2.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.